PRIMARY STUDY
Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption
Key Findings: Resulting data led the authors to conclude that cannabis use affects eCB “tone” in ulcerative colitis (UC) patients and may have beneficial effects on disease symptoms in UC patients.
Type of Study: Clinical Trial
Study Sample Size: 49
Study Result: Positive
Research Location(s): Canada, France, Israel
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG), Cannabinoid (unspecified), Palmitoylethanolamide (PEA)
Phytocannabinoid Source: Cannabis Flower derived
Chemotype: Chemotype I, Chemotype II, Chemotype III
Sub-Ratio: UC patients: 23:<1 (THC:CBD) CD Patients: 1:4 (THC:CBD)
Dosage: UC patients: each cannabis cigarette contained 0.5 g of dried cannabis flowers ( 23% THC and <0.5% CBD), equivalent to 11.5 mg of THC. CD Patients: cannabis oil 8 mg/ml CBD and 2 mg/ml THC.
Route of Administration: Inhalation, Oral (Ingestion)
Citation: Tartakover Matalon S, et al. Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption. Front Endocrinol (Lausanne). 2021; 12:685289. doi: 10.3389/fendo.2021.685289
Authors: Tartakover Matalon S, Azar S, Meiri D, Hadar R, Nemirovski A, Abu Jabal N, Konikoff FM, Drucker L, Tam J, Naftali T
